Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TPST-1120 Monotherapy and with Nivolumab in Advanced Solid Tumors
NCT03829436Phase 1Completed
- Sponsor
- Tempest Therapeutics
- Start
- Mar 2019
- Primary completion
- Sep 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of amezalpat in solid tumor, hepatocellular carcinoma (HCC), renal cell carcinoma (RCC) and 10 more (4 arms), sponsored by Tempest Therapeutics. Primary endpoints: Incidence of Dose Limiting Toxicities up to 36 months, Incidence of Treatment-Emergent Adverse Events up to 36 months and 1 more. Started Mar 2019; status: completed.
02
Drugs
amezalpat
03
Conditions
solid tumorhepatocellular carcinoma (HCC)renal cell carcinoma (RCC)cholangiocarcinoma (CCA)prostate cancer (PCa)
Beyond the preview
Go deeper on NCT03829436.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03829436.